Skip to main content
logo
Mirion Technologies, Inc. (MIR)
NYSE: MIR · Real-Time Price · USD
19.23
+0.55 (2.94%)
Nov 3, 2026, 1:48 PM EST - Market open

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Cancer Care Revenue
246.70M237.00M228.10M
Other Medical Revenue
72.30M73.80M71.60M
Total Medical Revenue
319.00M310.80M299.70M
Nuclear Revenue
496.50M374.60M316.60M
Labs and Research Revenue
127.60M122.20M131.70M
Other Nuclear & Safety Revenue
136.50M117.80M112.80M
Total Nuclear & Safety Revenue
760.60M614.60M561.10M
Revenue (Total)
1.08B925.40M860.80M

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
North America Revenue
721.30M582.20M542.20M
Europe Revenue
344.30M327.60M305.60M
Asia Pacific Revenue
14.00M15.60M13.00M
Revenue (Total)
1.08B925.40M860.80M

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Product Revenue
827.20M690.60M643.10M
Service Revenue
252.40M234.80M217.70M
Revenue (Total)
1.08B925.40M860.80M

Adjusted EBITDA

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Adjusted EBITDA
122.30M116.40M104.60M
Nuclear & Safety Adjusted EBITDA
207.60M177.70M159.80M
Corporate & Other Adjusted EBITDA
-67.90M-66.20M-60.80M
Operating Income (Total)
64.30M51.50M24.80M

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Income from Operations
56.80M46.90M22.30M
Nuclear & Safety Income from Operations
111.90M101.10M78.90M
Corporate & Other Income from Operations
-104.40M-96.50M-76.40M
Operating Income (Total)
64.30M51.50M24.80M

Capital Expenditures

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Capital Expenditures
20.40M20.20M27.80M
Nuclear & Safety Capital Expenditures
19.50M18.70M17.70M
Corporate & Other Capital Expenditures
1.90M700.00K3.30M

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Remaining Performance Obligations (RPO)
1.25B1.10B811.90M
Remaining Performance Obligations (RPO) to be Recognized Over NTM
23.00%49.00%54.00%
Order Book
1.38B1.03B843.00M
Medical - Organic Revenue Growth
-3.10%2.60%
Nuclear & Safety - Organic Revenue Growth
-4.40%8.80%
Total Organic Revenue Growth
-3.90%6.60%